2012 Scrip 100: Survival of the fittest
This article was originally published in Scrip
It’s finally here. For a while, a dark cloud has been looming ominously over the industry and, on this occasion, when it rains, it pours. Billions of dollars in revenues are set to be washed away from the P&L sheets of leading pharmaceutical companies as some of their most prized assets, their blockbuster drugs, suffer the consequences of patent expiry.